Functional consequences of polymorphism of xenobiotic metabolising enzymes

Toxicology Letters

Volumn 102-103, Issue , 1998, Pages 155-160

  Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse effects; Genetic polymorphism; Ultrarapid metabolisers

Indexed keywords

ACYLTRANSFERASE; ALCOHOL DEHYDROGENASE; ALDEHYDE DEHYDROGENASE; CHOLINESTERASE; CYTOCHROME P450; CYTOCHROME P450 ISOENZYME; DIHYDROPYRIMIDINE DEHYDROGENASE; DIMETHYLNITROSAMINE DEMETHYLASE; DRUG METABOLIZING ENZYME; EPOXIDE HYDROLASE; ETHOXYRESORUFIN DEETHYLASE; GLUCURONOSYLTRANSFERASE; GLUTATHIONE TRANSFERASE; PHENACETIN O DEETHYLASE; THIOPURINE METHYLTRANSFERASE; UNSPECIFIC MONOOXYGENASE; XANTHINE OXIDASE;

ALLELE; CONFERENCE PAPER; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MUTATION; PHENOTYPE; PRIORITY JOURNAL; XENOBIOTIC METABOLISM;

CYTOCHROME P-450 ENZYME SYSTEM; GENE DUPLICATION; HUMANS; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 19244373921     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(98)00301-4     Document Type: Conference Paper

References (17)

1. Agúndez, J.A.G., Ledesma, M.C., Ladero, J.M., et al., 1995. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population. Clin. Pharmacol. Ther. 57, 265-269.
2. Aklillu, E., Persson, I., Bertilsson, L., Johansson, I., Rodrigues, F., Ingelman-Sundberg, M., 1996. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J. Pharmacol. Exp. Ther. 278, 441-446.
3. Bertilsson, L., Dahl, M.-L., Sjöqvist, F., et al., 1993. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet 341, 63.
4. Bertilsson, L., Dahl, M.-L., Ingelman-Sundberg, M., Johansson, I., Sjöqvist, F., 1995. Interindividual and interethnic differences in polymorphic drug oxidation - implications for drug therapy with focus on psychoactive drugs. In: Pacifici, G., Fracchia, G.N. (Eds.), Advances in Drug Metabolism in Man. EUR 15439 EN, EC, DGXII-E-4. Office for Publications of the European Commission, Luxembourg, 1995, pp. 85-136.
5. Dahl, M.-L., Johansson, I., Bertilsson, L., Ingelman-Sundberg, M., Sjöqvist, F., 1995. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. J. Pharmacol. Exp. Ther. 274, 516-520.
6. Dalén, P., Dahl, M.-L., Ruiz, M.L.B., Nordin, J., Bertilsson, L., 1998. 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther. 63, 444-452.
7. Gram, L.F., Brösen, K., Sindrup, S., Skjelbo, E., 1995. Genetic and interethnic variability in drug metabolism: what are the clinical consequences. In: Alvan, G., Balant, L.P., Bechtel, P.R., Boobis, A., Gram, L.F., Paintaud, G., Pithan, K. (Eds.), European Conference on Specificity and Variability in Drug Metabolism. COST B1. Office for Official Publications of the European Communities EU, Luxembourg, 1995, pp. 235-245.
8. Heim, M.H., Meyer, U.A., 1990. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336, 529-532.
9. Henderson, C.J., Smith, A.G., Ure, J., Brown, K., Bacon, E.J., Wolf, C.R., 1998. Increased skin tumorigenesis in mice lacking pi class glutathione S-transferases. Proc. Natl. Acad. Sci. USA 95, 5275-5280.
10. Ingelman-Sundberg, M., Johansson, I., 1995. The molecular genetics of the human drug metabolizing cytochrome P450s. In: Pacifici, G., Fracchia, G.N. (Eds.), Advances in Drug Metabolism in Man. EUR 15439 EN, EC, DGXII-E-4. Office for Publications of the European Commission, Luxembourg, 1995, pp. 543-586.
11. Johansson, I., Bertilsson, L., Dahl, M.-L, Sjöqvist, F., Ingelman-Sundberg, M., 1993. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc. Natl. Acad. Sci. USA 90, 11825-11829.
12. Johansson, I., Oscarson, M., Yue, Q.-Y., Bertilsson, L., Sjöqvist, F., Ingelman-Sundberg, M., 1994. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46, 452-459.
13. Masimirembwa, C.M., Persson, I., Bertilsson, L., Hasler, J.A., Ingelman-Sundberg, M., 1996. Molecular basis of diminished debrisoquine hydroxylase (CYP2D6) activity in a black African population: a common mutation in exon 2 of the CYP2D6 gene. Br. J. Clin. Pharmacol. 42, 713-719.
14. McLellan, R.A., Oscarson, M., Seidegård, J., Price Evans, D.A., Ingelman-Sundberg, M., 1997a. Frequent occurrence of CYP2D6 gene duplication in Saudi Arabia. Pharmacogenetics 7, 187-191.
15. McLellan, R., Oscarson, M., Alexandrie, A.-K., Seidegård, J., Evans, D.A.P., Rannug, A., Ingelman-Sundberg, M., 1997b. Characterization of a human glutathione S-transferase mu cluster containing a duplicated GSTM1 gene causing ultrarapid enzyme activity. Mol. Pharmacol. 52, 958-965.
16. Oscarson, M., Hidestrand, M., Johansson, I., Ingelman-Sundberg, M., 1997. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function. Mol. Pharmacol. 52, 1034-1040.
17. Rannug, A., Alexandrie, A.-K., Persson, I., Ingelman-Sundberg, M., 1995. Genetic polymorphism of cytochrome P450 1A1, 2D6 and 2E1. Regulation and toxicological significance. J. Occup. Environ. Med. 37, 25-36.